The Bristol/HengRui guessing game begins
What could be the four HengRui assets picked up by Bristol?
Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
New prostate cancer hopes from Roche and Novartis
GDC-1261 and INR731 enter phase 1, but how do they act?
Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
